On Monday, December 16, the next meeting of the Transparency Council.
Agenda
- Prepare a position paper on the evaluation of the drug Jardiance (empagliflozinum) for the indication:
- Chronic kidney disease in adult patients:
- With eGFR in the range of ≥20 ml/min/1.73 m² to <45 ml/min/1.73 m², taking ACEi/ARB-based therapy for at least 4 weeks or with a contraindication to such therapy.
- With an eGFR of ≥45 ml/min/1.73 m² to <90 ml/min/1.73 m² and albuminuria or proteinuria, taking ACEi/ARB-based therapy for at least 4 weeks or with a contraindication to such therapy.
- Chronic kidney disease in adult patients:
- Prepare a position paper on the evaluation of the drug Jar...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at english@medexpress.pl.
If you already have an account, please log in
